ENTX - CIK 0001638097
Entera Bio Ltd. trades as ENTX. In its fiscal 2025 annual report the company posted revenue of $42.00K, down 76.8% from the prior year and net income of -$11.44M. This page tracks Entera Bio Ltd. through 382 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 5 fiscal years Entera Bio Ltd.'s revenue declined from $365.00K to $42.00K, a compound annual decline rate of 35.1%. Net profit margin compressed from -3072.9% to -27235.7% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| EFFECT | - | 2026-05-15 |
| 424B3 | - | 2026-05-15 |
| PRE 14A | - | 2026-05-14 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
| Securities registration | S-3 | 2026-05-08 |
| Quarterly report | 10-Q | 2026-05-08 |
The largest companies sharing Entera Bio Ltd.'s SEC industry classification (biological products, (no diagnostic substances)).
Entera Bio Ltd. reported revenue of $42.00K for fiscal year 2025, a decrease of 76.8% year over year.
In its latest fiscal year Entera Bio Ltd. reported a net loss of $11.44M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.